.jpg){kind=logo}
77th Tobacco Science Research Conference
September 14-17, 2025Knoxville Convention CenterKnoxville, Tennessee USA
Charlene Liu
President and Chief ScientistRiskwise Solution LLC
Dr. Liu is a renowned expert in regulatory strategy development and nonclinical studies for tobacco harm reduction products. She brings nearly a decade of leadership experience in toxicology and risk assessment at Reynolds Services Company, JUUL Labs, and RELX International.With nearly 20 years of prior experience in human health risk assessment at Environmental Protection Agency Superfund sites, Dr. Liu was one of the pioneers in applying quantitative risk assessment (QRA) to evaluate the relative health risks of tobacco harm reduction products over a decade ago. She has successfully developed and applied QRA methodologies for Premarket Tobacco Application (PMTA) for electronic nicotine delivery system (ENDS) and oral nicotine pouch products. Her work has influenced the FDA to adopt QRA as a key component in evaluating toxicological risk in ENDS PMTA for regulatory decisions on appropriate for the protection of public health (APPH).Dr. Liu founded Riskwise Solution, a consulting firm providing expertise in nonclinical science, including chemical characterization, long-term stability, toxicology, and risk assessment, to help clients navigate the evolving PMTA regulatory landscape.
Dr. Liu is a renowned expert in regulatory strategy development and nonclinical studies for tobacco harm reduction products. She brings nearly a decade of leadership experience in toxicology and risk assessment at Reynolds Services Company, JUUL Labs, and RELX International.With nearly 20 years of prior experience in human health risk assessment at Environmental Protection Agency Superfund sites, Dr. Liu was one of the pioneers in applying quantitative risk assessment (QRA) to evaluate the relative health risks of tobacco harm reduction products over a decade ago. She has successfully developed and applied QRA methodologies for Premarket Tobacco Application (PMTA) for electronic nicotine delivery system (ENDS) and oral nicotine pouch products. Her work has influenced the FDA to adopt QRA as a key component in evaluating toxicological risk in ENDS PMTA for regulatory decisions on appropriate for the protection of public health (APPH).Dr. Liu founded Riskwise Solution, a consulting firm providing expertise in nonclinical science, including chemical characterization, long-term stability, toxicology, and risk assessment, to help clients navigate the evolving PMTA regulatory landscape.